Table 5.
Summary of systolic blood pressure model fits using a tolerance model
| Subject | Emax (%Δ) | EC50 (µg l−1) | γe | Imax (%Δ) | IC50 (µg l−1) | γi | ki0 (h−1) |
|---|---|---|---|---|---|---|---|
| 1 | 68.2 | 121 | 3.6 | 44.2 | 93.0 | 5.3 | 3.6 |
| 2 | 54.8 | 250 | 1.5 | 18.4 | 46.5 | 6.0 | 0.6 |
| 3 | 36.4 | 73.3 | 2.2 | 43.5 | 71.3 | 1.0 | 1.2 |
| 4 | 52.9 | 115 | 2.2 | 31.3 | 79.6 | 2.3 | 0.3 |
| 5 | 29.9 | 123 | 0.6 | 9.6 | 41.0 | 8.1 | 6.4 |
| 6 | 38.6 | 134 | 0.9 | – | – | – | – |
| 7 | 99.9 | 91.5 | 1.5 | 82.9 | 81.8 | 1.4 | 4.2 |
| 8 | 49.0 | 46.8 | 2.3 | 48.9 | 43.0 | 1.9 | 3.1 |
| Mean | 53.7 | 107 | 1.9 | 39.8 | 65.2 | 3.7 | 2.8 |
| SD | 22.2 | 69.0 | 1.0 | 23.9 | 21.3 | 2.7 | 2.2 |
| Median | 50.9 | 103 | 1.9 | 43.5 | 71.3 | 2.3 | 3.1 |
| Mean without subject 6 | 55.9 | 103 | 2.0 | 39.8 | 65.2 | 3.7 | 2.8 |
| Pooled* | 64.2 | 174 | 1.9 | 26.5 | 90.6 | 2.8 | 2.0 |
Emax, maximum effect; EC50, plasma ephedrine concentration corresponding to one-half the maximum effect, γe, slope factor for the effect, Imax, maximum inhibitory effect; IC50, theoretical ‘inhibitor’ concentration corresponding to one-half the maximum inhibitory effect, γi, slope factor for the inhibitory effect; ki0, rate constant of tolerance development;
*
parameters derived by modelling data from all subjects (n = 8).